IGM Bio­sciences cuts 22% of work­force, ax­es hema­to­log­ic on­col­o­gy pro­gram

IGM Bio­sciences is not on­ly re­duc­ing its work­force by about 22%, but it is al­so ax­ing its clin­i­cal de­vel­op­ment pro­gram in hema­to­log­ic on­col­o­gy as well …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER